Migaldendranib (MGB), an investigational nanomedicine by Ashvattha Therapeutics, shows promise for treating diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD). In phase II results presented by Susan Schneider at the EURETINA Congress, MGB demonstrated a strong safety profile with no serious adverse events linked to the drug. The study revealed significant improvements in visual acuity and central subfield thickness, with a potential for at-home administration. MGB's unique mechanism sets it apart from traditional anti-VEGF therapies.
False
Advertisement
Related Content
Newsletters
Receive the latest Ophthalmology news, personalities, education, and career development – weekly to your inbox.
False
Advertisement